StudyID,Drug_Name,Disease,Disease_Stage,Prevalence,Age_Min,Age_Max,Prior_Line,Relapsed,Refractory,Geno_Biomarker,Comp_Biomarker,Other_Biomarker,ECOG,Karnofsky,Kidney_Func,Hepatic_Func,Hemo_Func,Cardio_Func,Comorb_Prohib,Concom_Prohib,Baseline_Severity_Score,Gender_Criteria,Washout_Period,Pregnancy_Lactation,Diag_Dis_Detect,Diag_Dis_Subtyp,Diag_Molecular,Diag_Histologic,Diag_Radiographic,Diag_Physiologic,Prog_High_Risk,Prog_Strat,Prog_Molecular,Prog_Inflamm,Prog_Histologic,Prog_Circulat,Pred_Enrich,Pred_Oncogenic,Pred_Response,Pred_Others,Safety_Hema,Safety_Hepa,Safety_Renal,Safety_Cardiac,Safety_Immune,Digit_Actig,Digit_Physio,Digit_Vocal,Digit_Cognit
NCT00387465,Azacitidine 30mg/m2; Entinostat; Azacitidine 40mg/m2,Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,,,18,,,,,,,,,,,,,,,,,Both,,,,,,,,,,,,,,,,,,,,,,,,,,,
